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by-nc-nd/3.0/).Summary Background: Although malaria can be prevented with prophylaxis, it is diagnosed
in over 100 Africa-region Peace Corps Volunteers annually. This suggests that prophylaxis non-
adherence is a problem in these non-immune travelers.
Methods: We investigated Volunteers’ knowledge, attitudes, and practices regarding prophy-
laxis using an internet-based survey during August 19eSeptember 30, 2013. Adherence was
defined as taking doxycycline or atovaquoneeproguanil daily, or taking mefloquine doses no
more than 8 days apart.
Results: The survey was sent to 3248 Volunteers. Of 781 whose responses were analyzed, 514
(73%) reported adherence to prophylaxis. The most common reasons for non-adherence were
forgetting (nZ 530, 90%); fear of long-term adverse effects (LTAEs; nZ 316, 54%); and expe-
riencing adverse events that Volunteers attributed to prophylaxis (nZ 297, 51%). Two hundred
fourteen (27%) Volunteers reported not worrying about malaria. On multivariate analysis con-
trolling for sex and experiencing adverse events Volunteers attributed to prophylaxis, the fac-
tor most strongly associated with non-adherence was being prescribed mefloquine (OR 5.4, 95%
confidence interval 3.2e9.0).
Conclusions: We found moderate adherence and a prevailing fear of LTAEs among Volunteers.
Strategies to improve prophylaxis adherence may include medication reminders, increasing ed-
ucation about prophylaxis safety and malaria risk, and promoting prompt management of pro-
phylaxis side effects.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).4) 718 4701 (office).
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Since 1961, over 215,000 Peace Corps Volunteers (Volun-
teers) have served worldwide, 46% of them in Africa. Most
Volunteer deployments last 27 months. As long-term trav-
elers to this area, Africa-region Volunteers are at high risk
for malaria infection. Peace Corps policy requires Volun-
teers in malaria-endemic countries to take malaria pro-
phylaxis. However, malaria is diagnosed in over 100 Africa-
region Volunteers each year, suggesting that non-
adherence to prophylaxis is a problem in this population
of non-immune travelers.
Concerns about adverse effects of prophylaxis, which
are reported by many Volunteers and other travelers to
malaria-endemic areas, are suspected to play a large role in
non-adherence. In a cross-sectional study of 2701 Volun-
teers conducted between 2005 and 2006, 62% of re-
spondents reported having a side effect that they
attributed to prophylaxis, and 28% reported changing pro-
phylaxis as a result [1]. In a 2003 randomized, double-
blinded, placebo-controlled study of 623 non-immune,
short-term travelers to sub-Saharan Africa, 85% of partici-
pants reported a side effect of prophylaxis [2]. It is unclear
what proportion of symptoms attributed to prophylaxis are
truly side effects of the medicine rather than normal events
related to long-term travel: in a randomized, double-
blinded, placebo-controlled study of mefloquine versus
atovaquoneeproguanil in 1013 patients presenting to travel
clinics in 1999, 62% of treatment-emergent adverse effects
were determined by the investigators to be unrelated to
the study drug [3]. Studies of adherence to long-term ma-
laria prophylaxis in populations of travelers have shown
that adherence is poor overall, and that fear of long-term
adverse effects (LTAEs), conflicting advice, and compli-
cated or daily dosing strategies are common reasons for
non-adherence [4,5].
The U.S. Centers for Disease Control (CDC)-recom-
mended options for prophylaxis in Africa are mefloquine,
doxycycline, and atovaquoneeproguanil (Malarone).
From as early as 1995 until 2012, Peace Corps policy rec-
ommended mefloquine as the drug of choice for Volunteers
without a history of psychiatric illness serving in Africa re-
gion countries. In December 2012, in response to concerns
on mefloquine safety expressed by some Volunteers, and in
hopes of increasing overall adherence, the policy was
changed to make all prophylaxis options equally available.
Peace Corps Medical Officers (PCMOs) are responsible for
Volunteer education pre-deployment about the use and
importance of uninterrupted prophylaxis, selection of pro-
phylaxis, and management of long-term use of prophylaxis
for the duration of Volunteers’ service [6]. They are
instructed to individualize their choice of agent based on
area-specific recommendations (e.g., some Volunteers
serve in regions where CDC does not recommend malaria
prophylaxis), drug contraindications and precautions, drug
tolerance, and dosing schedules. According to Peace Corps
policy, Volunteers non-adherent to prophylaxis can be
terminated from their Peace Corps service. Peace Corps has
followed this policy.
Between July 7 and September 30, 2013, CDC conducted
qualitative and quantitative evaluations among activeVolunteers with the aim of identifying risk factors for non-
adherence to malaria prophylaxis. We present the findings
of the quantitative evaluation.
2. Methods
In July 2013, we conducted focus-group discussions with
convenience samples of 30 active, consenting Volunteers in
Zambia, a country with high rates of malaria among Vol-
unteers (3.9 cases per 100 Volunteer years in 2012 [7]), and
Senegal, a country with low rates of malaria among Vol-
unteers (0.8 cases per 100 Volunteer years in 2012). We also
conducted interviews with these countries’ PCMOs and
each country’s Peace Corps directorship. Content of these
evaluations centered around participants’ views on and
personal experience with malaria and malaria prophylaxis,
sources for health advice, views on Peace Corps adminis-
tration policies, and Volunteer-PCMO relationships. CDC
staff used transcripts of these discussions to develop an
internet-based survey using SurveyMonkey (SurveyMonkey,
Palo Alto, CA). A survey was deployed August 19, 2013 by
the Peace Corps offices of all 23 countries with active posts
in the Africa region to all active Volunteers in-country. The
survey was open until September 30, 2013, and completed
anonymously by consenting Volunteers.
The survey contained questions on currently prescribed
malaria prophylaxis and dosing; current symptoms attrib-
uted to prophylaxis and feared LTAEs (adverse effects
occurring after Peace Corps as a result of taking prophylaxis
during Peace Corps); reasons for taking, not taking, or
changing prophylaxis; malaria diagnosis, testing, and care
history during Peace Corps service; knowledge and atti-
tudes related to Peace Corps policies regarding non-
adherence, malaria, and medication in general; country/
region of service; use of tobacco and recreational drugs,
and general demographics. Peace Corps-Headquarters
provided aggregate, anonymous demographic data on Vol-
unteers in countries where the survey was implemented.
These data included median age, gender distribution,
number of first- and second-year Volunteers in each coun-
try, and case rates of laboratory-confirmed malaria from
the year 2012.
Responses were received from Volunteers serving in all
countries in the region, including six countries where ma-
laria endemicity is non-uniform enough that CDC’s pro-
phylaxis recommendations vary within the country:
Ethiopia, Kenya, Tanzania, Namibia, Botswana, South Af-
rica. Although Peace Corps recommends malaria prophy-
laxis for all Volunteers serving in Ethiopia, Tanzania, and
Kenya, Volunteers in all six of these countries may have had
contact with people who were appropriately counseled not
to take prophylaxis. Because this might have affected their
attitudes toward prophylaxis, we excluded all respondents
from these six countries.
Descriptive analysis was conducted using SAS 9.3 (SAS
Institute, Cary, NC). Adverse events were grouped by organ
system for portions of the analysis: neuropsychiatric
symptoms were defined as nightmares/vivid dreams, anxi-
ety, insomnia, dizziness/vertigo, depression, limb numb-
ness, psychosis, headache, and tinnitus; gastrointestinal
symptoms were defined as heartburn, nausea/vomiting,
Table 1 Volunteer participation and malaria case rates by
country.
Country Volunteers
participating
Case rates of confirmed
malaria among country
Volunteers, 2012 [7]
(cases/100 Volunteers)
N (%)
Togo 29 (3.7) 13.1
Sierra Leone 49 (6.3) 7.9
Uganda 61 (7.8) 7.6
Liberia 44 (5.6) 5.2
Malawi 16 (2.0) 4.6
Cameroon 89 (11.4) 4.6
Benin 80 (10.2) 4.1
Burkina Faso 15 (1.9) 4.1
Zambia 47 (6.0) 3.9
Mozambique 35 (4.5) 3.6
Ghana 84 (10.8) 3.5
Rwanda 42 (5.4) 1.5
The Gambia 34 (4.4) 1.2
Senegal 26 (3.3) 0.8
The Gambia 25 (3.2) 0
Madagascar 87 (11.1) 0
Swaziland 18 (2.3) 0
Malaria prophylaxis among Peace Corps Volunteers 63diarrhea, mouth ulcers, constipation, and dyspepsia;
dermatologic symptoms were defined as sun sensitivity,
rash, acne changes, and other skin complaints; genitouri-
nary symptoms were defined as yeast infections and urinary
disturbances; and consistutional symptoms were defined as
hair loss, weight changes, and fever). For Volunteers pre-
scribed mefloquine, adherence was defined as taking doses
of the medication no more than eight days apart. For those
prescribed atovaquoneeproguanil or doxycycline, adher-
ence was defined as taking the medication once a day at
any time of day. Odds ratios were calculated for all major
factors assessed in the survey. Factors significant on crude
analysis were further analyzed using multivariate logistic
regression to identify predictors of non-adherence.
3. Results
3.1. Geography and demographics
An email describing and linking to an online Volunteer survey
was sent to 3248 Volunteers across 23 countries in the Africa
region, 2307 of them serving in countries with uniform pro-
phylaxis recommendations. We received 1184 unique, valid
responses to the survey between August 19th and September
30th, 2013. After excluding 193 respondents who did not
identify the country in which they were serving and 210 from
countries with non-uniform prophylaxis recommendations,
survey data from 781 respondents remained, yielding a
response rate of 34%. Volunteers from countries with uni-
form recommendations were more likely to be<26 years old
than those from countries with non-uniform recommenda-
tions (59% vs. 45%, X2 Z 12.6, p < 0.001), and were more
likely to have served >1 year in Peace Corps (61% vs. 31%,
X2Z 92.1, p < 0.001); there were no statistically significant
differences in sex between the groups.
To determine whether geographic differences in malaria
incidence among Volunteers were associated with differ-
ences in response rates, we compared country response
rates with malaria case rates reported by each country’s
PCMO team. There was no correlation between response
rates and case rates (Spearman rho 0.13, p Z 0.67;
Table 1).
To determine the representativeness of the Volunteers
included in the study compared to survey invitees, we
compared median age, proportion female, and years of
service between the two groups. The median age group of
included Volunteers was 22e25 years, comparable to 25
years among invitees. Five hundred twenty-six (68%)
included Volunteers were female, compared to 2069 (64%)
invitees (p Z 0.028), and 307 (39%) were in their first year
of service, compared to 1515 (47%) invitees (p < 0.001).
3.2. Adherence to prophylaxis
Three hundred eighty Volunteers (49%) reported being
prescribed mefloquine, 304 (39%) doxycycline, and 97 (12%)
atovaquoneeproguanil. Two hundred seventy-six (35%) re-
spondents reported having changed prophylaxis at some
point during their service.
Of 703 respondents reporting how often they take their
prescribed prophylaxis, 514 (73%) reported taking it inadherence with their prescribed dosing regimen. Adher-
ence was 90% among those prescribed atovaquoneepro-
guanil (n Z 77), 84% (n Z 231) among those prescribed
mefloquine, and 60% (n Z 206) among those prescribed
doxycycline.
Thirty-eight (5%) and 29 (4%) respondents reported tak-
ing prophylaxis only seasonally and only when traveling
away from their posts, respectively, and 335 (72%) females
and 174 (75%) males reported adherence. Among all age
groups, adherence was lowest in respondents aged 22e25
years.
3.3. Reasons for non-adherence
The most commonly cited reason for adherence to pro-
phylaxis was the perception that the prophylaxis prescribed
was effective at preventing malaria (n Z 747, 98%). The
most common reasons for non-adherence were forgetting
to take prophylaxis (n Z 530, 90%), fear of long-term
adverse events (n Z 316, 54%), and having experienced
adverse effects they attributed to prophylaxis (n Z 297,
51%). Other reasons for adherence and non-adherence are
listed in Table 2.
Among those who reported forgetting as a reason for
non-adherence, the most commonly reported setting was
travel or another disruption in routine (n Z 266, 49%).
Among those who forgot prophylaxis while traveling, not
bringing prophylaxis (nZ 232, 87%) was more common than
bringing prophylaxis and forgetting to take it (nZ 39, 15%).
Two hundred seventy-six (38%) of 724 Volunteers
acknowledged fear of having LTAEs after their Peace Corps
service. The LTAEs most commonly feared were neuropsy-
chiatric problems (n Z 155, 56%), unspecified problems
(n Z 101, 37%), cancer (n Z 32, 12%), and sun sensitivity
Table 2 Reasons for adherence and non-adherence malaria prophylaxis cited by Volunteers.
Reason for adherence to malaria
prophylaxis medication
Volunteers Reason for non-adherence to
malaria prophylaxis medication
Volunteers
N (%) N (%)
I think the medication is effective
at preventing malaria
747 (98) I forget to take the prophylaxis 530 (90)
I’m worried about what would
happen to my health if I get malaria
706 (93) I am worried about having health
problems after Peace Corps as a
result of prophylaxis
316 (54)
The PCMO told me to take the
medication
687 (90) I have side effects of the
prophylaxis when I take it
297 (51)
It is PC policy that I should take
the medication
662 (87) I do other things that are enough
to keep me from getting malaria
217 (37)
I’m in an area where there are a lot
of mosquitoes/malaria
649 (85) I haven’t had side effects, but
worry I would have them
167 (29)
The malaria training in the PSTa convinced
me it was a good idea
643 (85) I don’t think I’m in an area where
there are a lot of mosquitoes/malaria
165 (28)
I heard about someone dying of malaria
and feared for myself
557 (73) I’ve gotten conflicting advice about
whether the prophylaxis was necessary
158 (27)
I fear being administratively separated
if I get caught not taking it
540 (71) I only take the prophylaxis seasonally 147 (25)
I saw someone sick with malaria
and feared for myself
520 (68) It’s too hard to switch prophylaxis 134 (23)
Other PCVs Volunteers told me to
take the medication
373 (49) I’m not that worried about what will
happen to my health if I get malaria
131 (22)
My doctor at home told me to take
the medication
317 (42) I worry that prophylaxis is ineffective
malaria prevention
110 (19)
I have had malaria 17 (2) I worry about the prophylaxis
interacting with other meds I use
108 (18)
I like the side effects of the medication 3 (0) I worry about interaction with alcohol 81 (14)
Prophylaxis is easy to take 3 (0) I don’t think it’s right for me to be
at lower risk for malaria than the
population I’m living with
59 (10)
I am a STOMP Volunteer and fear being
a hypocrite if I get malaria while in service
1 (0) I worry about interaction with
recreational drugs
18 (3)
I don’t want to be a vector in my community 1 (0) Unreliable food availabilityb 8 (1)
Changes in routine 3 (1)
Unsteady supply of prophylaxis 2 (0)
Gastrointestinal side effects 1 (0)
Fear of antibiotic resistance due
to prolonged antibiotic use
1 (0)
Concern for interaction with dairy 1 (0)
a PST, pre-service training.
b Volunteers described taking prophylaxis, especially doxycycline, only with a large meal to avoid gastrointestinal toxicity.
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cerned about liver problems as an LTAE of prophylaxis.
Of 733 Volunteers, 359 (49%) experienced adverse events
during Peace Corps service that they attributed to pro-
phylaxis: 219 (61%) were prescribed mefloquine, 133 (37%)
were prescribed doxycycline, and 7 (2%) were prescribed
atovaquoneeproguanil. Of all 380 patients prescribed
mefloquine, 215 (57%) attributed a neuropsychiatric event
to the drug, most commonly nightmares/vivid dreams,
anxiety, and insomnia. Adverse events most commonly re-
ported by those prescribed doxycycline were sun sensi-
tivity, nausea/vomiting, and heartburn, and those most
commonly reported by those prescribed atovaquoneepro-
guanil were nausea/vomiting, nightmares/vivid dreams,
and insomnia (Table 3, column percents).Among all Volunteers experiencing any adverse event
they attributed to prophylaxis, neuropsychiatric events
were reported by 242 (67%), while 118 (33%) reported
gastrointestinal events, 102 (28%) reported dermatologic
events, 66 (18%) reported constitutional events, and 37
(10%) reported genitourinary events. Among neuropsychi-
atric adverse events reported, nightmares/vivid dreams,
anxiety, and insomnia were most common. All adverse
events attributed to prophylaxis irrespective of respondent
adherence are listed in Table 3.
Among Volunteers who did not experience adverse
events that they attributed to their prophylaxis, adherence
to atovaquoneeproguanil was 91% (n Z 72), adherence to
doxycycline was 90% (n Z 128), and adherence to meflo-
quine was 74% (n Z 94).
Table 3 Adverse events attributed to prophylaxis among all Volunteers attributing any adverse event (n Z 359) and by
prescribed drug.
Adverse event Total Prescribed prophylaxis
N % Atovaquone-proguanil Doxycycline Mefloquine
n Row %a Column %b
(N Z 7)
n Row % Column %
(N Z 133)
n Row % Column %
(N Z 219)
Neuropsychiatric 242 (67) 4 (2) (57) 23 (10) (17) 215 (89) (98)
Nightmares/vivid dreams 181 (50) 2 (1) (29) 6 (3) (5) 173 (96) (79)
Anxiety 111 (31) 2 (2) (29) 5 (5) (4) 104 (94) (48)
Insomnia 104 (29) 2 (2) (29) 8 (8) (6) 94 (90) (43)
Dizziness/vertigo 55 (15) 0 (0) (0) 3 (5) (2) 52 (95) (24)
Depression 43 (12) 0 (0) (0) 4 (9) (3) 39 (91) (18)
Limb numbness 29 (8) 1 (3) (14) 1 (3) (1) 27 (93) (12)
Psychosis 6 (2) 0 (0) (0) 0 (0) (0) 6 (100) (3)
Headache 30 (8) 1 (3) (14) 6 (20) (5) 23 (77) (11)
Tinnitus 4 (1) 0 (0) (0) 0 (0) (0) 4 (100) (2)
Gastrointestinal 118 (33) 3 (3) (43) 83 (70) (62) 32 (27) (15)
Dermatologic 105 (28) 1 (1) (14) 96 (94) (72) 5 (5) (2)
Constitutional 66 (18) 1 (2) (14) 12 (18) (9) 53 (80) (24)
Genitourinary 37 (10) 1 (3) (14) 34 (92) (26) 2 (5) (1)
Total having any adverse event 359 (100) 7 (2) (100) 133 (37) (100) 219 (61) (100)
a Row percent is the number of those reporting an adverse event while prescribed a certain drug divided by the total number of people
reporting the side effect (row N is the denominator).
b Column percent is the number of those who reported a specific adverse event divided by the total number of those reporting any
adverse event while prescribed a certain drug (N listed in the “column %” heading for each drug is the denominator).
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behaviors
Of Volunteers answering questions on their knowledge
about morbidity/mortality risks related to malaria, 758
(99%) correctly indicated that it was possible to die from
malaria and 636 (97%) correctly indicated that it is possible
to get permanent disability from malaria. Only 61 (10%)
indicated that it was highly likely a person would die if they
became infected with malaria, and 74 (12%) indicated that
it was possible to become immune to malaria by being
infected with malaria.
Two hundred fourteen (27%) Volunteers indicated they
were not worried about malaria, most often because they
believed malaria can be treated quickly (n Z 181, 85%).
Other common reasons were knowing non-host country
nationals (HCN; nZ 93, 44%) or HCN (nZ 71, 33%) who had
survived malaria, the belief that malaria is treatable and
not a serious disease (n Z 4, 20%), and having personally
survived malaria (n Z 48, 22%).
Seventy-nine (10%) Volunteers reported having been
diagnosed with malaria during their Peace Corps service,
and 332 (43%) acknowledged having had at least one malaria
test during their service. Although 119 (15%) Volunteers had
been tested for malaria by their PCMO, 201 (26%) had been
tested for malaria elsewhere, and 69 (9%) had been tested
for malaria with a rapid diagnostic test (RDT) not supplied by
Peace Corps. Thirty-three (4%) Volunteers had taken an
antimalarial drug not prescribed by Peace Corps.
When asked whom they would contact first when ill, 461
(59%) Volunteers answered, “a PCMO.” Two hundred twenty-
five (29%) Volunteers acknowledged having called theirPCMO with malaria symptoms, while 114 (15%) Volunteers
acknowledged having had malaria symptoms without calling
the PCMO. Nine (1%) Volunteers acknowledged having lied to
the PCMO about an RDT result for any reason.
Nineteen (2%) Volunteers reported using recreational
drugs at least once a week. Six hundred ninety-eight (91%)
Volunteers answering questions about chronic medications
indicated they either were taking long-term medications or
would take long-term medications, or that it could be
appropriate to take a medication for disease prevention.
3.5. Bivariate and multivariate analysis
Factors significantly associated with non-adherence on
bivariate analysis are listed in Table 4. For the purpose of
multivariable modeling, we excluded Volunteers prescribed
malarone due to the relatively small number in this group.
Treatment-seeking behavior, such as seeking diagnosis
outside of PCMO care or self-treatingwith non-PC drugs, were
not associated with nonadherence. In a model controlling for
sex and experiencing adverse events that they attributed to
prophylaxis, factors significantly associated with higher odds
of non-adherence were being prescribed mefloquine (OR 5.4,
95% confidence interval [CI] 3.2e9.0), not being worried
about malaria (OR 2.6, 95% CI 1.6e4.1), having been in Peace
Corps service >1 year (OR 1.8, 95% CI 1.2e2.8), and being
<26 years old (OR 1.7, 95% CI 1.1e2.6; Table 4).
4. Discussion
The most common reason Volunteers gave for non-
adherence was simply forgetting, suggesting a role for
Table 4 Factors associated with non-adherence.
Bivariate analysis Multivariate analysis
Unadjusted ORa (95% CIb) Adjusted OR (95% CI)
Mefloquine prescribed 3.5 2.4e5.1 5.4 3.2e9.0
Not worried about malaria 3.3 2.2e4.8 2.6 1.6e4.1
>1 years of Peace Corps service 1.8 1.2e2.5 1.8 1.2e2.8
Age <26 years 1.8 1.2e2.6 1.7 1.1e2.6
Attribute adverse events to prophylaxis 1.9 1.2e2.8 1.5 0.9e2.3
Sex female 1.2 0.8e1.8 1.0 0.6e1.6
Had malaria symptoms during Peace Corps but did not call the PCMOc 2.1 1.3e3.3 e e
Diagnosed with malaria during Peace Corpsc 1.9 1.1e3.3 e e
Fear LTAEsc 1.6 1.1e2.4 e e
Would take long-term medications for preventive purposesc 0.5 0.3e0.9 e e
Feel is it likely to die from malaria infectionc 0.3 0.1e0.8 e e
a OR Z Odds ratio.
b CI Z confidence interval.
c Not included in final multivariable model.
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self-managing medication or automated reminders, and
could potentially include an SMS reminder system similar to
those used throughout rural Africa for antiretroviral ther-
apy [8].
Fear of long-term adverse effects was another important
reason for non-adherence. The top adverse effect feared
by Volunteers was “unspecified problems,” and the next
five most commonly feared symptoms were neuropsychi-
atric. When these five symptoms were cited as feared
LTAEs, over 80% of the time it was by Volunteers prescribed
mefloquine. Although mefloquine is known to cause
neuropsychiatric effects in 10e15% of people while it is
being taken [9,10], published data demonstrating meflo-
quine side effects presenting or persisting after discontin-
uation of the medication are limited to several case reports
of ototoxicity [11]. Serious adverse events due to meflo-
quine are rare [12]. On July 29, 2013, the Food and Drug
Administration (FDA) added a black-box warning to meflo-
quine labeling, advising providers and patients about the
reports of long term ototoxicity.
About half of the Volunteers in our study attributed
adverse events to their malaria prophylaxis, and the drug
with the largest proportion of adverse events attributed
was mefloquine (59%). In other studies, mefloquine adverse
effects have been reported by 62% [1] and 67% [3] of adult
subjects taking the drug. The three most commonly drug-
attributed adverse events in our cohort were neuropsychi-
atric, and were also most commonly reported by Volunteers
prescribed mefloquine. Neuropsychiatric events have been
previously associated with mefloquine: in a randomized,
double-blind trial comparing mefloquine to atovaquonee-
proguanil, 29% of subjects taking mefloquine had any
neuropsychiatric event [3]. In that trial, 14% of those taking
atovaquoneeproguanil also reported neuropsychiatric
events. Because atovaquoneeproguanil is not considered to
be a cause of neuropsychiatric side effects, these findings
suggest that overattribution of adverse events to medica-
tions may be a concern in antimalarial drug safety studies.
Compared to that trial, a higher proportion of our re-
spondents (56%) reported neuropsychiatric events,especially vivid dreams, anxiety, and depression. Several
reasons may exist for this. First, Volunteers experiencing
adverse events attributed to prophylaxis or with heightened
concern for LTAEsmay have beenmoremotivated to respond
to the survey, resulting in skewed measures of association.
Second, substantial overlap exists between mefloquine side
effects and symptoms associatedwith the stressors innate to
Peace Corps service. Although these symptoms may be
physiologic, Volunteers may identify them as a side effect of
prophylaxis. Finally, many Volunteers are aware of meflo-
quine’s side effects due to increased publicity via the pop-
ular press, blogs, and social media. For example, although
the FDA black box warning for mefloquine was issued only a
month before the survey, several Volunteers were aware of
the warning. The availability of Internet-based information
sources among Volunteers compared to that among partici-
pants in other studies may be higher. Frequent recreational
drug use was acknowledged by only 2% of respondents.
Although this behavior may have been underreported, it
seems unlikely to be a contributor to increased reporting of
neuropsychiatric symptoms. Negative perceptions of mef-
loquine related to these sources may explain our finding that
being prescribed mefloquine was the single factor most
strongly associated with non-adherence on multivariable
analysis, even when controlling for experienced adverse
events attributed to prophylaxis. Under Peace Corps’ new
policy allowing Volunteers equal access to all prophylaxis
options, it may be easier for Volunteers who prefer a non-
mefloquine option to change medications. Meanwhile, Vol-
unteers who prefer the medication due to its weekly
administration or for other reasons will be able to continue
using it.
Atovaquoneeproguanil is a daily medication with few
side effects [3,13], and few Volunteers experienced
adverse events they attributed to it. Although this is a safe
medication for many, its dosing and cost should be
considered.
Of note, among reasons for non-adherence, Volunteers
ranked concern for interaction with alcohol and other
medications (including oral contraceptives) relatively low.
No evidence exists to support the interaction of
Malaria prophylaxis among Peace Corps Volunteers 67mefloquine, doxycycline, or atovaquoneeproguanil with
alcohol or oral contraceptives.
Almost all Volunteers knew that death and disability
were possible consequences of malaria infection. However,
27% of Volunteers acknowledged not being worried about
malaria, and this perception was associated with increased
odds of prophylaxis non-adherence. When detected and
treated early, malaria often has limited morbidity and
mortality. However, the risk of progression to severe illness
is not completely eliminated by early treatment, and in
remote areas, obtaining comprehensive early care for ma-
laria may be difficult. Volunteers must be educated on
these risks, emphasizing that prevention is essential.
The practice of attributing even low-grade symptoms to
malaria in their communities may lead to the perception
that malaria is not something to be concerned about. Vol-
unteers should be aware of malaria prevalence in their
communities, and of the importance of obtaining the best-
available healthcare, including proper diagnosis and treat-
ment for malaria symptoms.
Twelve percent of Volunteers indicated that they
thought it was possible to become immune to malaria by
being infected. Most Peace Corps tours are unlikely to
include sufficient malaria exposure to induce any mean-
ingful immunity, and there is no laboratory test to measure
partial immunity. The perception that repeated infections
reduce risk can lead to riskier behavior, including non-
adherence to prophylaxis.
The only health seeking behavior associated with non-
adherence on crude analysis was not calling a PCMO when
having malaria symptoms, reported by 15% of Volunteers
and more common among non-adherent Volunteers. This
practice can lead to delays in recognizing and treating
malaria, further increasing the risk of progression to severe
illness or death. Self-treatment of malaria was not associ-
ated with non-adherence, suggesting that non-adherers do
not seem to be relying on self-treatment in place of pro-
phylaxis. However, 4% of Volunteers acknowledged self-
treatment with drugs not provided by Peace Corpsda
concerning finding, given the high prevalence of counter-
feit antimalarial drugs in sub-Saharan Africa [14]. Volun-
teers should be educated about the risks of self-treatment.
In our study, 73% of Volunteers reported adherence to
antimalarial drugs; a relatively high proportion when
compared to other studies of malaria prophylaxis in long
term travelers with observed adherence between 59 and
62% of participants [5,15,16]). Volunteers younger than 26
years and with more than 1 year of Peace Corps experience
had increased odds of non-adherence to prophylaxis. This
may be explained by a greater sense of invulnerability in
this population, and similar findings have been documented
elsewhere: in a study of humanitarian workers, non-
adherence to malaria prophylaxis increased in a linear
fashion with the duration of mission, and was 81% in
workers who had served in missions lasting 12e18 months
[17]. Interventions to improve adherence in more experi-
enced Volunteers could include education both at the start
of service and as a refresher course mid-service, with a
focus on malaria morbidity and mortality and the important
benefits of preventive medication.
Some strengths of this study included its relatively rapid
execution, its dissemination to all Africa-region Volunteers,and its ability to measure multiple beliefs and behaviors.
However, there were several important limitations to this
study. First, the response rate among PCVs was only 34%,
and non-response bias might have affected the results.
Volunteers who were non-adherent might have been less
likely to participate, just as those who were adherent may
have been more likely to participate, possibly resulting in
the higher than expected proportion of respondents
adherent to prophylaxis. Second, because the study relied
on Internet access for survey completion, selection bias
might have occurred (e.g. selecting for Volunteers posted
to more urban areas or those with Internet-enabled de-
vices). Because older Volunteers are more likely to be
assigned to urban, well-resourced areas, this may have
resulted in relatively reduced input from younger Volun-
teers. Third, because Volunteers knew adherence was ex-
pected from them, social desirability bias might have
occurred. Finally, the exclusion of Volunteers from coun-
tries with geographically non-uniform prophylaxis recom-
mendations might have selected for Volunteers exposed to
fewer conflicting recommendations, resulting in participa-
tion of a non-representative population.
Although it is possible that Volunteers who feel more
personally threatened by malaria may have been more
likely to complete our survey, there was no statistically
significant correlation between 2012 malaria case rates and
response rate to our survey. It is unlikely there was a
relationship between malaria incidence among a country’s
Volunteers and their likelihood of responding to our survey.
On the basis of our findings, we have presented several
strategies to improve malaria prophylaxis adherence in
Peace Corps Volunteers and other long-term travelers to
malaria-endemic countries, among them education that
targets common fears and rumors about prophylaxis drugs,
and automated or other reminder systems. The training
curriculum delivered by PCMOs to Volunteers has already
been updated and standardized, and Peace Corps is initi-
ating evaluation studies to assess the impact of training
(Barry G. Simon, MD, Peace Corps Medical Director; per-
sonal communication; August 2013). Given the importance
of feared LTAEs in motivating non-adherence, there is a
need for further study on this subject.
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